VivoPower secures Mpox diagnostic tests distribution heads of agreement for Singapore, Hong Kong and Australia with Sansure Biotech Inc

Core Insights - VivoPower International PLC has announced a distribution agreement with Sansure Biotech Inc for Mpox diagnostic tests and detection kits in Singapore, Hong Kong, and Australia, with potential expansion to other markets [1][2] - The agreement is part of VivoPower's business continuity planning to ensure employee safety and maintain supply chains for partners and customers [2] - VivoPower, as a certified B Corporation, emphasizes a commitment to the triple bottom line of People, Planet, and Profit, and plans to reinvest surplus profits from Mpox distribution into its sustainable energy solutions business [1][3][4] Company Overview - VivoPower, established in 2014 and listed on NASDAQ since 2016, focuses on sustainable energy solutions, including electric fleet applications and ancillary services [6][7] - The company operates in multiple regions, including Australia, Canada, the Netherlands, the United Kingdom, the United States, the Philippines, and the United Arab Emirates [7] - VivoPower's core mission is to provide turnkey decarbonisation solutions to help customers achieve net-zero carbon status [7] Industry Context - The World Health Organization declared the Mpox outbreak a public health emergency on August 14, 2024, with significant case numbers reported globally, particularly in Africa [5] - Sansure Biotech Inc, established in 2008 and listed on the Shanghai Stock Exchange, specializes in in vitro diagnostic solutions and has a market capitalization exceeding US$1 billion [8]